Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.	20549
------------------	-------

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL		
OMB Number:	3235-0287	
Estimated average burden		
hours per response:	0.5	

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer 1. Name and Address of Reporting Person' (Check all applicable) Tyra Biosciences, Inc. [TYRA] Harris Todd Director X 10% Owner Officer (give title Other (specify 3. Date of Earliest Transaction (Month/Day/Year) (Middle) helow) below) (Last) (First) 09/15/2023 President and CEO C/O TYRA BIOSCIENCES, INC. 2656 STATE STREET 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person (Street) Form filed by More than One Reporting 92008 **CARLSBAD** CA Person Rule 10b5-1(c) Transaction Indication (City) (State) (Zip) Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 2A. Deemed 1. Title of Security (Instr. 3) 2. Transaction 5. Amount of 6. Ownership 7. Nature Form: Direct Execution Date, Securities Beneficially (Month/Day/Year) 5) if any Code (Instr. (D) or Indirect Beneficial (Month/Day/Year) 8) Owned Following Reported (I) (Instr. 4) Ownership (Instr. 4) (A) or (D) Transaction(s) Code ν Amount Price (Instr. 3 and 4) Common Stock 09/15/2023 A⁽¹⁾ 1,421 \$6.579 1,602,697 D A Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of 3. Transaction 3A. Deemed Execution Date, 5. Number 6. Date Exercisable and 7. Title and 8. Price of 9. Number of 10. 11. Nature Conversion Derivative Transaction **Expiration Date** Amount of Derivative derivative Ownership of Indirect Derivative Security or Exercise (Month/Day/Year if any Code (Instr. (Month/Dav/Year) Securities Security Securities Form: **Beneficial**

Explanation of Responses:

Derivative

Security

1. These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

Remarks:

(Instr. 3)

/s/ Ali D. Fawaz, Attorney-in-

** Signature of Reporting Person

Derivative

Title

Security (Instr. 3 and 4)

Amount Number

Shares

Fact

Expiration

Date

Exercisable

09/19/2023

(Instr. 5)

Beneficially

Following Reported

Date

Transaction(s) (Instr. 4)

Owned

Direct (D)

or Indirect (I) (Instr. 4)

Ownership (Instr. 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Month/Day/Year)

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Securities Acquired

(A) or Disposed

of (D) (Instr. 3, 4

and 5)

(A) (D)